Phase 1, open-label, multicenter, dose escalation study of SRG-1505 as monotherapy in subjects with mature b-cell malignancies

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-505204-34-00

Acronym

SRG-1505-101

Enrollment

Registered

2023-09-27

Start date

2024-12-30

Completion date

Unknown

Last updated

2025-10-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ALK-Positive Large B-Cell Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma (DLBCL), Diffuse large B-cell lymphoma (DLBCL) Germinal Center B-Cell Type, Duodenal-Type Follicular Lymphoma, Epstein-Barr virus (EBCV)–positive diffuse large B-cell lymphoma (DLBCL), Follicular Lymphoma, HHV8-Positive Diffuse large B-cell lymphoma (DLBCL), High-grade B-cell Lymphoma, Large B-cell lymphoma with IRF4 rearrangement, MALT Lymphoma, Mantle Cell Lymphoma, Mature B-Cell Neoplasm, Nodal Marginal Zone Lymphoma, Non-Hodgkin Lymphoma, Nos, Nos Lymphoplasmacytic Lymphoma, Pediatric-Type Follicular Lymphoma, Plasmablastic Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma (DLBCL), Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Splenic Marginal Zone Lymphoma, T-Cell/Histiocyte-Rich Lymphoma, Waldenstrom Macroglobulinemia

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

France, Italy, Poland, Romania, Spain

Outcome results